Lunsekimig

Lunsekimig (SAR443765) is Sanofi's wholly-owned bispecific Nanobody that hits two pillars of Type 2 inflammation in a single molecule: TSLP (the upstream alarm signal from epithelial cells) and IL-13 (a downstream tissue effector driving mucus, smooth muscle contraction, fibrosis, and skin barrier dysfunction). Phase 2 topline data released April 2026 was mixed: the AIRCULES moderate-to-severe asthma study and DUET chronic rhinosinusitis with nasal polyps study met their primary endpoints, while the VELVET atopic dermatitis study (NCT06790121, n=150) missed its primary endpoint of percent change in EASI at week 24 but showed improvement on the secondary EASI-75 response rate and vIGA-AD 0/1 clear/almost clear measures [1][12]. Two Phase 3 trials in eosinophilic COPD (PERSEPHONE, THESEUS) launched in 2025 are now recruiting ~1,900 patients combined [4][5]. The strategic prize: Sanofi splits Dupixent profits with Regeneron, while lunsekimig is wholly-owned - an attempt to capture the next-generation Type 2 inflammation franchise outright, but the AD primary miss complicates the dermatology pillar of that thesis.

Novel compound, first-in-class for the IL-13/TSLP bispecific format. The atopic dermatitis trial referenced by the node (NCT06790121, VELVET, Phase 2b, n=150) tested three subcutaneous dose regimens with percent change in EASI score at week 24 as primary [1]. Topline announced 2026-04-07: primary endpoint missed, but secondary endpoints (EASI-75 - the proportion of patients achieving a 75% reduction in eczema severity score - and vIGA-AD 0/1) improved versus placebo with favorable tolerability [12]. The CRSwNP proof-of-concept DUET study (NCT06454240, n=79) met its primary endpoint of change in bilateral nasal polyp score at week 24 plus key secondary measures including Lund-Mackay CT score and patient-reported nasal congestion [3][12]. The AIRCULES Phase 2b asthma study (NCT06676319, n=1147) met primary endpoint of annualized exacerbation rate reduction plus pre-bronchodilator FEV1 improvement [2][12]. Two parallel Phase 3 COPD trials in patients with eosinophilic phenotype launched in 2025 (NCT07190222 PERSEPHONE and NCT07190209 THESEUS, each n=942), targeting the same regulatory path Dupixent used for its September 2024 COPD label [4][5][11]. The AIRLYMPUS Phase 2 high-risk asthma program is also advancing [12]. No FDA breakthrough or fast-track designations have been publicly disclosed. Lunsekimig's first-in-human safety and pharmacokinetics and asthma proof-of-mechanism are published in Clinical and Translational Science 2024 and European Respiratory Journal 2025 [6][7].

Type 2 inflammation works as a cascade. Epithelial cells (the lining of skin and airways) release alarmins when irritated - TSLP (thymic stromal lymphopoietin) is the loudest. TSLP licenses dendritic cells and drives Th2 cell differentiation, which produces IL-4, IL-5, and IL-13. IL-4 is the primary driver of IgE class switching in B cells and of Th2 commitment itself. IL-13 is the workhorse tissue effector: it drives mucus secretion, smooth muscle contraction in airways, fibrotic remodeling, and breakdown of the skin barrier in atopic dermatitis (IL-13 contributes only modestly to IgE class switching - IL-4 dominates that step via the IL-4Rα/γc receptor). Block TSLP, you mute the alarm and reduce upstream Th2 priming including IL-4 release. Block IL-13, you stop the dominant tissue effector. Lunsekimig does both with one molecule built from camelid single-domain antibody fragments (Nanobodies), the format Sanofi acquired from Ablynx in 2018. The validation case is strong on each target separately. AstraZeneca's tezepelumab (anti-TSLP) is approved for severe asthma [10]. Dupilumab (anti-IL-4Rα, which blocks both IL-4 and IL-13 signaling) is approved across atopic dermatitis, asthma, COPD, nasal polyps, EoE, and prurigo nodularis [11]. Lebrikizumab and tralokinumab (anti-IL-13 monoclonal antibodies) are approved in atopic dermatitis. Open Targets ranks IL-13 at 0.73 evidence for atopic eczema and 0.66 for asthma. The Phase 1b proof-of-mechanism in asthma (PMID 39884759) showed reductions in FeNO (fractional exhaled nitric oxide, a validated surrogate for eosinophilic airway inflammation) and blood eosinophils consistent with both arms engaging biology [6]. Mechanistically, lunsekimig differs from dupilumab in a meaningful way: dupilumab blocks IL-4 + IL-13 jointly via IL-4Rα, while lunsekimig blocks IL-13 + TSLP - a different combinatorial bet on which axis dominates a given disease.

The node references NCT06790121 (VELVET) - Phase 2b, double-blind, placebo-controlled, n=150, subcutaneous lunsekimig tested across three dose regimens, moderate-to-severe atopic dermatitis, primary endpoint percent change in EASI score from baseline to week 24 [1]. Sample size is small but standard for AD proof-of-concept; week 24 is the right timepoint for biologics. Notable gap: no biomarker preselection (no enrichment for IgE-high or eosinophil-high patients), which limited the ability to identify responder subgroups when the overall primary endpoint missed [12]. Endpoint context: EASI-75 (75% reduction in Eczema Area and Severity Index) is the conventional efficacy bar in dermatology - Dupixent's key trials cleared roughly 44-51% EASI-75 at 16 weeks, and lebrikizumab/tralokinumab cleared similar ranges. The broader program is more ambitious. NCT06676319 (AIRCULES) in moderate-to-severe asthma at n=1147 is Phase 2b/3 scale, with annualized asthma exacerbation rate as primary - defined as attacks per patient-year, the standard exacerbation prevention endpoint that normalizes for trial length to allow comparison across studies [2]. The two Phase 3 COPD studies (PERSEPHONE NCT07190222 and THESEUS NCT07190209) require eosinophilic phenotype, mirroring the BOREAS/NOTUS approach that worked for dupilumab in COPD [4][5]. The CRSwNP study (DUET, NCT06454240) used bilateral endoscopic nasal polyp score change as primary, matching dupilumab's SINUS-24/52 endpoint design [3]. The trial portfolio is competent and follows established Type 2 inflammation playbooks across four indications.

Our model estimates this drug has a 15% chance of eventually being approved. It starts from the historical approval rate for drugs at this stage (about 30%), then adjusts based on ten specific facts about the trial and its sponsor. The estimate is pulled up by an unusually large number of secondary endpoints and the sponsor's strong approval track record, but pulled down by weak early-phase results and heavier-than-usual blinding. The remaining factors were close to average and left the estimate largely unchanged.

Efficacy risk has now partially resolved with mixed data. Asthma and CRSwNP Phase 2 hits validate the dual-blockade approach in respiratory and ENT indications [12]. The AD primary endpoint miss exposes the central question: does IL-13/TSLP blockade actually deliver deeper or more durable responses than blocking either alone, particularly in skin where IL-4-driven IgE and dupilumab's IL-4Rα block may be doing more of the work? Sanofi's own anti-IL-33 antibody itepekimab (SAR440340) had mixed Phase 2 outcomes in COPD, illustrating that mechanism validation in one Type 2 indication does not guarantee success in another. The IL-13 plus TSLP combination has never been tested as a co-administered monoclonal pair, so we still lack a head-to-head counterfactual. Safety risk is modest and now partly de-risked. Lunsekimig Phase 2 topline showed favorable tolerability across all three studies, with serious adverse event rates similar to placebo and nasopharyngitis, upper respiratory infections, and injection site reactions as common findings [12]. Conjunctivitis (a known dupilumab issue tied to IL-13 blockade) appears at similar incidence. Nanobody immunogenicity is generally low after humanization but not zero. Commercial risk is the biggest issue. Dupixent generated ~€13.1B (~$14B+) in 2024 net product sales and is deeply entrenched across six indications, with prescriber familiarity, payer coverage, and patient assistance programs already in place [9]. Lunsekimig has to show real incremental benefit - deeper responses, faster onset, longer dosing intervals - to displace Dupixent or even share the market. Sanofi faces an internal cannibalization question: if lunsekimig wins, it eats Dupixent revenue Sanofi already keeps half of, replacing it with revenue Sanofi keeps in full. The AD primary miss makes the differentiation case harder - at best, lunsekimig joins lebrikizumab/tralokinumab as another IL-13 option in dermatology. Competitive overhang: Roche's astegolimab (anti-ST2, blocking IL-33 signaling) is in Phase 3 for severe asthma and COPD and is another late-stage Type 2 inflammation contender that did not previously appear in the competitive landscape.

Worth watching, with the economics now more nuanced. Sanofi splits Dupixent 50/50 with Regeneron; lunsekimig is wholly-owned. The April 2026 Phase 2 readouts shift the strategic calculus: respiratory and CRSwNP wins de-risk the COPD Phase 3 program (PERSEPHONE/THESEUS), which targets the largest commercial opportunity - eosinophilic COPD is where dupilumab currently has the only approval (September 2024) [11]. The AD primary endpoint miss weakens the dermatology pillar. The specific data points that matter from here: full EASI-75, vIGA-AD, and dose-response data from VELVET when Sanofi presents at AAD or EADV (likely fall 2026), including any biomarker-stratified responder signal. The COPD Phase 3 readouts in 2027-2028 are the bigger commercial event. Timing is the critical strategic constraint: Dupixent's earliest US composition-of-matter patent expires October 2027, with method-of-use patents extending into 2030-2031 and patent term extension potentially reaching ~2031 [13]. Biosimilar dupilumab is in development by multiple manufacturers, with US market entry expected early-to-mid 2030s. If lunsekimig takes another 4-6 years to reach broad approval across multiple indications, its commercial window opens just as biosimilar pricing pressure on dupilumab begins - meaning the 'wholly-owned' margin advantage erodes against a reference product that is itself being undercut. Sanofi's $50B+ topline gives runway to develop patiently; the strategic question is whether 'patiently' is fast enough to capture meaningful share before the Type 2 inflammation market repricies.